Rev Esp Quimioter 2022;35(Suppl.3):16-19

Neutralizing antibodies for SARS-CoV-2 infection

JUAN BERENGUER

Published: 24 October 2022

http://www.doi.org/10.37201/req/s03.04.2022

The COVID-19 pandemic has boosted significant research in developing monoclonal antibodies (mAbs) to treat and prevent SARS-CoV-2 infection. Clinical trials have shown that mAbs are safe and effective in preventing hospitalization and death in patients with mild to moderate COVID-19 risk factors for progression. mAbs have also been effective for treating severe disease in seronegative patients and preventing COVID-19. So far, studies have been carried out in a largely unvaccinated population at a time when the omicron variant was not described. Future research should address these limitations and provide information on specific population groups, including immunosuppressed and previously infected individuals.

Rev Esp Quimioter 2022; 35(Suppl.3):16-19 [Full-text PDF]